Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
Overview of PerkinElmer Inc.
PerkinElmer Inc. is a globally recognized scientific instrumentation and solutions provider that serves the needs of researchers, clinicians, and scientists in diagnostics, life sciences, and applied markets. With decades of expertise, the company combines state-of-the-art technology with deep industry knowledge to deliver instruments and software that empower precise and early insights in analytical and diagnostic processes.
Core Business Areas
PerkinElmer specializes in multiple business areas, including:
- Diagnostics: Offering advanced tools and methodologies designed to support early disease detection and accurate diagnostics.
- Life Sciences: Providing instrumentation and support services that enhance biological research, drug discovery, and genomic studies.
- Food and Applied Markets: Delivering practical solutions tailored to food safety, environmental monitoring, and quality control.
Business Model and Revenue Generation
The company operates by integrating advanced science and technology with customer-focused services, generating revenue through direct sales of high-performance analytical instruments, licensing of proprietary technologies, and ongoing service contracts. The business model emphasizes long-term customer partnerships and continuous innovation, which are vital in meeting the evolving needs of global research communities.
Market Position and Competitive Landscape
Positioned as a significant player in the scientific instrumentation sector, PerkinElmer competes with other global providers by offering an extensive portfolio of integrated solutions. Its competitive edge stems from its deep technical expertise, robust customer service, and strategic investments in research and development. This approach not only addresses current market challenges but also establishes a broad framework that supports complex research endeavors and regulatory needs.
Technological Innovation and Expertise
At its core, PerkinElmer leverages cutting-edge technologies to enable breakthrough discoveries in science and healthcare. The company continuously evolves its product offerings through innovation in instrument design, software integration, and application-specific solutions. These innovations are a direct result of its commitment to deep market insight and technical expertise, ensuring that its customers benefit from the latest advances in scientific research.
Global Reach and Impact
With a presence in numerous countries worldwide, the company functions as a key enabler in global research efforts. By providing technologies that support both clinical and research applications, PerkinElmer contributes significantly to improving healthcare outcomes and advancing scientific understanding. Its global footprint allows it to serve a diverse array of industries, reinforcing its role as a vital partner in enhancing quality of life through scientific progress.
Commitment to Quality and Customer Partnership
PerkinElmer is dedicated to building strategic partnerships with its customers, offering tailored support and service solutions that meet the specific requirements of complex research and diagnostic projects. This commitment is reflected in its holistic approach to customer engagement, combining product excellence with expert consultancy and robust technical assistance.
Conclusion
In summary, PerkinElmer Inc. encapsulates a sophisticated blend of innovation, market insight, and operational excellence. It remains an influential entity in the scientific and healthcare sectors by consistently providing analytical instrumentation and solutions that empower users to achieve early and accurate results. The company’s ability to integrate advanced technology with practical applications makes it an indispensable partner for global research institutions and healthcare providers alike.
PerkinElmer, a leader in health innovation, will present at the Cowen 42nd Annual Health Care Conference and the Barclays Global Healthcare Conference. The Cowen conference is scheduled for March 7, 2022, with Jamey Mock, CFO, presenting at 10:30 a.m. ET. Following this, Prahlad Singh, CEO, will present at the Barclays conference on March 15, 2022, at 1:30 p.m. ET in Miami. Both presentations will provide insights on the company's strategic priorities, with live audio webcasts available on their website, where replays will also be accessible for 90 days post-event.
PerkinElmer, a leader in health innovation, will present at Citi’s Virtual Healthcare Conference on February 24, 2022, at 8:45 a.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. Interested participants can register here. A live webcast will also be available on the Investors section of the company’s website, with a replay accessible for 90 days post-event.
PerkinElmer reported $5.0 billion in revenue for 2021 and operates in 190 countries.
EUROIMMUN, a subsidiary of PerkinElmer (NYSE:PKI), announced the inclusion of its Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) test in the CDC's pre-vaccination screening for the Dengvaxia vaccine. This test is crucial for ensuring that children aged 9-16, who have a laboratory-confirmed previous dengue infection, can access the vaccine in dengue-endemic areas. In 2019, dengue cases reached record levels, emphasizing the need for effective diagnostic solutions. The assay focuses on virus-specific antibodies, enabling better vaccination strategies against dengue disease.
PerkinElmer reported 4Q 2021 revenue of $1.36 billion, reflecting a 1% reported growth but a -9% organic growth. GAAP EPS from continuing operations was $1.41, down from $3.38 in 4Q 2020. For the full year, GAAP revenue reached $5.067 billion, up from $3.783 billion in 2020, boasting a 32% increase. The company also announced its 2022 guidance, projecting first-quarter revenue between $1.17-$1.19 billion and full-year revenue of $4.42-$4.50 billion.
The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of
PerkinElmer, Inc. (NYSE: PKI) anticipates exceeding its fourth quarter 2021 revenue and earnings guidance. Expected adjusted earnings per share is at least
PerkinElmer (NYSE: PKI) is set to present virtually at the J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. The company's CEO, Prahlad Singh, will discuss strategic priorities and provide an update on operations. A live audio webcast will be accessible via the provided link, and a replay will be available on the PerkinElmer Investor Relations website for 30 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 16,000 staff globally, serving customers in 190 countries.
PerkinElmer, a leader in health innovations, has launched the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 for accelerated detection of SARS-CoV-2 variants, including Omicron. The kit enhances sequencing throughput and reduces turnaround time by three hours for 96 samples through advanced normalization beads. It incorporates 1,536 Unique Dual Index barcodes, allowing for the sequencing of 6,000 libraries in a single flow cell, lowering costs. This initiative aims to support SARS-CoV-2 surveillance efforts amid the ongoing pandemic.
PerkinElmer, Inc. (NYSE: PKI) announced that its SARS-CoV-2 RT-PCR assays remain effective despite the emergence of the Omicron variant of concern.
With over 30 reported mutations in the S gene, the company's assays do not target this gene and are unaffected by these changes. In silico assessments indicate no impact on diagnostic accuracy from the Omicron variant.
The company emphasizes the importance of reliable diagnostics amid ongoing concerns regarding transmissibility and vaccine resistance. PerkinElmer's solutions include a comprehensive SARS-CoV-2 portfolio.
PerkinElmer, a global leader in health innovation, will present at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET. Prahlad Singh, the Company’s CEO, will discuss strategic priorities and provide a company update. Interested parties can register for the event here. A webcast will be available on PerkinElmer's Investor website, with a replay accessible for 90 days post-event.
FAQ
What is the market cap of PERKINELMER (PKI)?
What core markets does PerkinElmer Inc. serve?
How does PerkinElmer generate its revenue?
What distinguishes PerkinElmer from its competitors?
How does PerkinElmer contribute to advancements in healthcare and research?
What is the significance of PerkinElmer's focus on innovation?
In which regions does PerkinElmer operate?
How does PerkinElmer support its customer base?
What industry-specific expertise does PerkinElmer offer?
